

- pathogenesis of, 433e-1, 433e-1f
with progressive skeletal myopathy and/or cardiomyopathy
 Danon's disease, 432e-2t, 432e-4t, 433e-5, 1566
 PRKAG2 deficiency, 433e-2t, 433e-5
 type II. *See* Pompe disease (acid α -1,4 glucosidase deficiency)
- Glycolysis
 abnormalities of, 462e-14, 650f, 653–654
 anaerobic bacterial, 461
 in heart muscle, 265e-10
- Glycopeptides, 930, 931t, 942
- Glycoprotein gp120, 214e-3
- Glycoprotein hormones, 400e-1
- Glycoprotein Ib/IX, 372e-25t
- Glycoprotein Ib-IX-V complex, 275–276, 741–742
- Glycoprotein IIb/IIIa, 401, 745, 746f, 748
- Glycoprotein IIb/IIIa antagonists. *See also specific drugs*
 adverse effects of, 749
 discontinuation before lumbar puncture, 443e-1
 dosage of, 749
 indications for, 749
 for myocardial infarction, 1596, 1606
 in PCI, 296e-1
 pharmacology of, 749t
- Glycoprotein IIb/IIIa receptors, 276, 725, 742
- Glycoprotein IIb/IIIg, 372e-25t
- Glycoproteinosis(es), 432e-3t
- Glycopyrrolate, 2643
- Glycosphingolipidoses, neutral, 432e-3t
- Glycosuria, 299, 332e-7t
- Glycylcyclines. *See* Tigecycline
- Glycyrrhizic acid, 64e-8, 306, 307
- GMAP (Global Malaria Action Plan), 14
- GM-CSF (granulocyte-macrophage colony-stimulating factor), 372e-11t, 414f, 416–417
- GM-CSF therapy. *See* Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy
- GM gangliosides, 372e-24t
- GNA11* gene mutations, 2475
- GNAS1* gene mutations, 426e-6, 430, 437, 2344
- GNAS* gene mutations, 2315, 2486
- Gnathostoma spinigerum*/gnathostomiasis
 clinical features of, 908t, 1412–1413
 diagnosis of, 245e-6t, 765t, 1413
 epidemiology of, 765t, 1412
 treatment of, 1411t, 1413
- Gnotobiotic, 86e-1t, 86e-7
- GnRH. *See* Gonadotropin-releasing hormone (GnRH)
- GnRH1* gene mutations, 2363
- GnRHR* gene mutations, 2363, 2364t
- GOBI, 8
- GOBI-FFF, 8
- Goblet cells, 86e-8
- Goiter, **2301**
- Goitrogens, 2301
- Goitrous thyroiditis. *See* Hashimoto's thyroiditis (autoimmune hypothyroidism)
- Gold, adverse effects of, 349, 361, 379, 727t, 2193, 2688t
- Golden Rice, 96e-7
- Golgin, 372e-24t
- Golimumab
 adverse effects of, 348t, 2146t, 2173
 for ankylosing spondylitis, 2172–2173
 for autoimmune and inflammatory diseases, 372e-30
 for IBD, 1961
 for psoriasis/psoriatic arthritis, 348t, 2177
 for rheumatoid arthritis, 2145, 2146t
- Gompertzian growth curve/kinetics, 102e-2, 103e-3f
- Gonadal development, 2349f, 2351f
- Gonadal dysgenesis, 2353
- Gonadal mosaicism, 433
- Gonadal sex, 2349, 2349f
- Gonadectomy, 336
- Gonadotropin(s), **401e-4**. *See also* Follicle-stimulating hormone (FSH); Luteinizing hormone (LH)
 action of, 401e-4
 deficiency of. *See* Hypogonadism
 in male reproductive function, 2360
 for ovulatory induction, 2389
 pituitary tumor production of, 2273–2274
 secretion of, 401e-4
 synthesis of, 401e-4
- Gonadotropin-releasing hormone (GnRH)
 action of, 401e-2f, 401e-4
 deficiency of. *See* Hypogonadotropic hypogonadism
 for hypogonadotropic hypogonadism, 337
 hypothalamic, 401e-1, 401e-2f
 in male pubertal development, 2357
 in menstrual cycle regulation, 2378
 in ovarian function regulation, 2376–2377, 2377f
 pulse frequency of, 400e-6, 401e-4
- Gonadotropin-releasing hormone (GnRH) analogues, 2362
- Gonadotropin-releasing hormone (GnRH) stimulation test, 2360
- Gonioscopy, 200
- Gonococcal arthritis. *See* Gonococcal infections, disseminated
- Gonococcal infections, **1003**
 anorectal, 1005–1006
 cephalosporin intermediate/resistant, 1005
 in children, 1006, 1008
 diagnosis of, 150e-6, 150e-8, 1007–1008
 disseminated
 clinical features of, 133t, 835, 1006, 1007f
 complications of, 1006
 epidemiology of, 133t, 1006
 joint involvement in, 1006, 1007t
 oral manifestations of, 238t
 risk factors for, 1006
 skin manifestations of, 25e-11f, 76e-13f, 133t, 135, 369, 1007f
 treatment of, 1008, 1009t
 epidemiology of, 869, 1003
 epididymitis, 872
 global considerations in, 1003, 1004
 in HIV infection, 1006–1007
 in men, 870–871, 881, 1005, 1005f
 in neonates, 1006, 1009t
 ocular, 1006, 1009t
 oral manifestations of, 238t
 pathogenesis of, 1003–1004. *See also* *Neisseria gonorrhoeae*
 pelvic inflammatory disease. *See* Pelvic inflammatory disease (PID)
 pharyngeal, 231, 1006, 1008, 1009t
 in pregnancy, 50, 1006, 1008
 prevention and control of, 1009
 quinolone-resistant, 1004
 screening for, 29t, 882
 spectinomycin-resistant, 1004–1005
 treatment of, 871, 872t, 1008, 1009t
 in women, 872, 1005
- Go-no go test, 183
- Gonorrhea. *See* Gonococcal infections
- Goodpasture's syndrome
 clinical features of, 377e-4, 1715, 1835t, 1836, 1839
 diagnosis of, 1839
 hemoptysis in, 245
 HLA gene association with, 373e-8t
 pathophysiology of, 372e-24t, 377e-4, 1715, 1833
 prognosis of, 1839
 treatment of, 1715, 1839
- Good's syndrome, 123e-1
- Gordon's syndrome. *See* Pseudohypaldosteronism type II (Gordon's syndrome)
- Gorlin formula, valve area measurement, 1463
- Gorlin's syndrome (nevoid basal cell carcinoma syndrome)
 clinical features of, 364t, 365, 599t
 genetic considerations in, 101e-6t, 599t, 602
- nonmelanoma skin cancer in, 500
 ovarian fibroma in, 594
- Goserelin, 103e-15, 585
- Gottron's sign, 374, 374f, 2195
- Gout, **2233**
 clinical features of, 2233
 diagnosis of, 2233–2234, 2234f
 drug-induced, 2218t
 genetic considerations in, 431e-3, 431e-3t
 hyperuricemia in, 431e-4
 inflammasome activity in, 372e-8t
 nephropathy in, 431e-4, 1862
 obesity and, 415e-6
 prevalence of, 431e-1, 431e-4
 tophaceous, 365, 436e-2f
 treatment of, 2234–2235
- Gou virus, 1307t
- Gowers' sign, 462e-1, 462e-3f
- gp41, 1230, 1244
- gp120, 1216, 1230, 1237
- gp160, 1237
- GPC regimen, for bladder cancer, 577
- GPCRs (G protein-coupled receptors), 212, 400e-1, 400e-1t, 2252
- GPI (glucose-6-phosphate isomerase) deficiency, 650f, 654t
- GPIHP1 deficiency, 2440, 2440t
- G protein(s), 400e-3, 400e-3f, 468e-1, 1613
- G protein-coupled receptors (GPCRs), 212, 400e-1, 400e-1t, 2252
- GRA. *See* Glucocorticoid-remediable aldosteronism (GRA)
- Graafian follicle, 2376f
- Graded exercise therapy, 153, 464e-2–3
- Gradenigo's syndrome, 209, 906
- Graft-versus-host disease (GVHD)
 chronic, 139e-4
 clinical features of, 139e-3
 CMV infection and, 921–922
 cobalamin malabsorption in, 646
 diarrhea in, 267, 270
 grading and staging of, 139e-3–4, 139e-3t
 incidence of, 139e-1
 prevention of, 138e-5, 139e-4
 skin manifestations of, 139e-3, 349, 353, 361, 362, 362t
 transfusion-associated, 138e-5, 664
 treatment of, 139e-4
- Graft-versus-tumor effect, 139e-1
- Graham Steell murmur, 51e-6, 1540, 1550
- Grain dust exposure, 1688t, 1691
- Gramicidin, 945t
- Grammar, assessment of, 177
- Gram-negative bacteria. *See also specific bacteria*
 antibiotic resistance in, 807, 933, 1026–1027
 antibiotic targets in, 932f
 diagnosis of, 150e-1, 150e-2t, 1026
 epidemiology of, 1025
 global considerations in, 1026–1027
 host interactions of, 1025, 1025t
 infections caused by, 1026, 1752t
 in sepsis/septic shock, 1752t
 structure and function of, 1025
- Gram-positive bacteria. *See also specific bacteria*
 antibiotic resistance in, 933
 antibiotic targets in, 932f
 diagnosis of, 150e-1, 150e-2t
 in sepsis/septic shock, 1752t
- Gram's stain, **150e-1**, 150e-2t, 806, 1085f
- Grandmother hypothesis, of aging, 94e-3
- Granisetron, 62, 103e-25, 109, 260, 260t
- Granular casts, 62e-11f
- Granular lymphocytes, 81e-2
- Granulicatella* spp., 821, 971
- Granulocyte(s), 81e-6f, 89e-3f, 419t. *See also* Eosinophil(s); Neutrophil(s)
- Granulocyte colony-stimulating factor (G-CSF), 372e-11t, 414f, 804
- Granulocyte colony-stimulating factor (G-CSF) therapy
 adverse effects of, 366, 379
 for AML, 686
 for aplastic anemia, 667
 in HSCT, 89e-1, 139e-1–2